Venture Capital

IT implementation failures that have dogged business and public sector organizations were the result of flawed processes, but a new approach promises to create greater alignment between business and technology, according to columnist Kirk Knoernschild. In this inaugural edition of Aligning IT, he touts the...

Angel investors play a critical role in the early-stage equity financing of high- growth entrepreneurial companies, and their activity continues to increase, according to an annual study by the Center for Venture Research at the University of New Hampshire. An annual study of angel investing...

The decision by NimbleGen Systems to file for an initial public offering may primarily be an exit strategy for its investors, but it's also the latest piece of a global sales strategy. Company officials have been mum on recent fund-raising developments, but they have also...

Improvements in purification technology are needed to help researchers determine the structure and function of enzymes and other proteins that play key roles in diseases, and a Madison biotech firm has received a federal grant to enable such improvements. Semba Biosciences will get $107,000 from...

GenTel Biosciences, a Madison-based protein chip maker, has acquired the protein chip platform assets of GlaxoSmithKline, one of the world's largest pharmaceutical companies. The platform will position GenTel to compete for drug-screening deals in the range of $1 million to $3 million. ...

The venture capital picture in Wisconsin, while improving, still lags behind other states that also are trying to grow knowledge-based economies, but venture capitalist Paul Carbone is among the optimists. Carbone, managing partner of Baird Venture Partners, says some historical perspective is needed to accurately...

For the second consecutive year, Milwaukee-based ZyStor Therapeutics has been selected to present at the annual InvestMidwest Venture Capital forum. The company, which is developing enzyme replacement therapies to treat rare genetic disorders, is looking to raise $15 million or more for Phase I clinical...

Despite the sparse attendance at a recent Midwestern biotechnology conference, columnist Michael Rosen believes there is room for a major bioscience cluster here. In this edition of Yer Biotech Blues, he examines the key ingredients necessary to have a successful world-class bioscience cluster in the...